Magic Mushroom Potency Varies Widely, Even Within Same Strain

A study conducted at the Shamir Research Institute, affiliated with the University of Haifa, has revealed significant variability in the psychoactive compound content of "magic mushrooms" (Psilocybe cubensis). Researchers found that the potency of these mushrooms, containing psilocybin and studied for potential mental health treatments, cannot be accurately predicted based on their weight or species name alone. The study, published in the Journal of Fungi, observed a difference of up to 7.8 times in the total concentration of active compounds between different strains of Psilocybe cubensis, despite being cultivated under identical laboratory conditions. Furthermore, considerable variations were also detected between individual mushrooms of the same strain grown together in the same batch.

Professor Eyal Korembaum of the Shamir Research Institute and Tel-Hai Academic College, a member of the research team, emphasized the need for careful strain selection and precise chemical analysis for reliable comparisons in future research and treatments. He noted that the observed variability, even within the same strain, is a crucial factor that must be considered in upcoming studies and therapies involving psilocybin mushrooms.

The research, funded by the Ministry of Innovation, Science and Technology, involved cultivating 14 strains of Psilocybe cubensis under uniform conditions. After harvesting, the mushrooms were freeze-dried, ground, and analyzed for six tryptamines, including psilocybin and psilocin. The total concentration of these compounds ranged from 2.62 to 20.65 milligrams per gram of dried mushroom. Psilocybin was the dominant compound, but its concentration and ratio to other substances varied considerably.

Even among individual mushrooms from the same batch, the variation in psilocybin concentration ranged from 12.81% to 23.39%. The researchers concluded that species name, strain name, and mushroom weight are insufficient predictors of active compound levels. This finding poses a challenge for developing standardized medicinal products from whole mushrooms and highlights the uncertainty for individuals using them outside of controlled settings.

Future research will focus on cultivating mushroom mycelium in bioreactors using liquid media, a method expected to yield more homogeneous products with greater control over psychoactive compound quantities. This approach, compared to the eight-week cultivation on solid media, can be reduced to just one week and is anticipated to offer a more consistent and controllable output for pharmaceutical and therapeutic applications.